Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CANCER

Financiado

Cerrado

Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improvi...

Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art f... ver más

31/08/2023

PERC

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

PERCUROS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

MSCA-RISE-2017: Research and Innovation Staff Excha...

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

PERC

378.00K€ | Lider

HEL2

162.00K€ | Participante

Progredum GmbH

108.00K€ | Participante

HELRIK

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ISPIC Image Guided Surgery IGS and Personalised Postoperative Im... 4M€ Cerrado

MultiTheranostic Theranostic magnetic nano-based codelivery system for boosti... Cerrado

RTC2019-006809-1 NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra... 583K€ Cerrado

Melomanes Combination therapy for the treatment of metastatic melanoma... Cerrado

SAF2014-54057-R DESARROLLO DE NANOMEDICINAS PARA TERAPIAS ANTITUMORALES E IN... 242K€ Cerrado

ONCOTHERANOSTICS Advanced Theranostic Nanomedicines for Oncology. Development... 257K€ Cerrado

Duración del proyecto: 69 meses Fecha Inicio: 2017-11-21
Fecha Fin: 2023-08-31

Líder del proyecto

PERCUROS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions. This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project: i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a lifetime of protection against cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores